FDA Approves Polarean’s XENOVIEW™ (xenon Xe 129 hyperpolarized) for use with MRI for the evaluation of lung ventilation
Polarean Imaging, a start-up founded by Dr. Bastiaan Driehuys (Radiology, SOM), has received FDA approval for its hyperpolarized xenon gas blend, trade name XENOVIEW.
Tellus Therapeutics Announces $35 Million Series A Financing
Tellus Therapeutics, a neonatal care company developing treatments for newborns in the neonatal intensive care unit (NICU), announced today the closing of a Series A financing round of $35 million led by the Perceptive Xontogeny…
Duke’s Daniel Dardani elected to the AUTM Board of Directors
As part of AUTM's Board of Directors, Duke's Daniel Dardani will help support and advance technology transfer worldwide.
Duke Angel Network is now Duke Capital Partners
Duke University’s early-stage venture investment arm, Duke Angel Network, is now Duke Capital Partners. Duke Capital Partners provides capital and expertise to help Duke startups, and features one of Duke’s most innovative experiential learning opportunities…
Translation and Commercialization reports another successful year
Duke University’s Office for Translation & Commercialization continues to grow and set new records for commercializing innovations, according to just-released fiscal year 2022 data.
Gore acquires InnAVasc Medical, Inc., a Duke startup
Developed by Jeff Lawson, MD, PhD and Shawn Gage, PA-C in Duke University School of Medicine’s Department of Surgery, the InnAVasc device is specifically designed to allow for safe, easy, reproduceable and durable access for…
Duke Technology Launches PFAS-Destroying Waste Treatment Company to Nasdaq
This article first appeared on the Pratt School of Engineering page, written by Ken Kingery. As he watched his business partner ring the opening bell of the Nasdaq Stock Market, Marc Deshusses couldn’t help but smile.…
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant
Radius first licensed the indication for this drug discovered out of the Donald McDonnell lab from Duke in 2017.
Evecxia Therapeutics Announces Leadership Transition to Support Next Phase of Development and Growth
Joseph M. Patti, Ph.D., Appointed President and CEO John J. Kaiser, Retires as CEO, Remains as Board Director RESEARCH TRIANGLE PARK, N.C., June 13, 2022–(BUSINESS WIRE)–Evecxia Therapeutics, a clinical stage biopharmaceutical company dedicated to realizing…